Lifecore Historical Income Statement
| LFCR Stock | 7.46 0.15 2.05% |
Historical analysis of Lifecore Biomedical income statement accounts such as Gross Profit of 50.2 M can show how well Lifecore Biomedical performed in making a profits. Evaluating Lifecore Biomedical income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Lifecore Biomedical's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Lifecore Biomedical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lifecore Biomedical is a good buy for the upcoming year.
Lifecore |
About Lifecore Income Statement Analysis
Lifecore Biomedical Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Lifecore Biomedical shareholders. The income statement also shows Lifecore investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Lifecore Biomedical Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Lifecore Biomedical generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Lifecore Biomedical minus its cost of goods sold. It is profit before Lifecore Biomedical operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Lifecore Biomedical. It is also known as Lifecore Biomedical overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Lifecore Biomedical's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Lifecore Biomedical current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lifecore Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.At this time, Lifecore Biomedical's Interest Income is relatively stable compared to the past year. As of 11/26/2024, Net Income From Continuing Ops is likely to grow to about 9.8 M, while Total Revenue is likely to drop slightly above 121.8 M.
| 2021 | 2023 | 2024 (projected) | Total Revenue | 185.8M | 128.3M | 121.8M | Interest Expense | 17.4M | 18.1M | 19.0M |
Lifecore Biomedical income statement Correlations
Click cells to compare fundamentals
Lifecore Biomedical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lifecore Biomedical income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | (4.3M) | 8.6M | 17.9M | 7.1M | 8M | 6.4M | |
| Interest Expense | 9.6M | 15.3M | 17.4M | 17.3M | 18.1M | 19.0M | |
| Total Revenue | 557.6M | 590.4M | 544.2M | 185.8M | 128.3M | 121.8M | |
| Gross Profit | 75.0M | 81.5M | 50.4M | 50.6M | 41.9M | 50.2M | |
| Other Operating Expenses | 598.7M | 538.3M | 189.4M | 185.7M | 135.4M | 128.7M | |
| Operating Income | (8.3M) | (6.9M) | (3.6M) | 3.5M | 9.3M | 5.7M | |
| Ebit | (8.3M) | 4.4M | (85.9M) | (5.1M) | (7.2M) | (6.8M) | |
| Research Development | 11.5M | 11.1M | 10.2M | 7.8M | 8.6M | 7.4M | |
| Ebitda | (12.6M) | 13.0M | (68.0M) | 2.0M | 812K | 771.4K | |
| Cost Of Revenue | 515.4M | 462.7M | 135.4M | 135.2M | 86.4M | 82.1M | |
| Total Operating Expenses | 83.3M | 75.6M | 54.0M | 50.5M | 49.0M | 42.6M | |
| Income Before Tax | (51.3M) | (40.5M) | (52.1M) | (51.9M) | 9.5M | 10.0M | |
| Total Other Income Expense Net | (43.0M) | (21.0M) | (48.5M) | (8.9M) | 183K | 192.2K | |
| Net Income | (38.2M) | (32.7M) | (97.4M) | (46.1M) | 12.0M | 12.6M | |
| Income Tax Expense | 1.5M | (13.1M) | (7.8M) | (5.8M) | 183K | 173.9K | |
| Selling General Administrative | 72.1M | 65.3M | 46.1M | 42.4M | 43.0M | 57.3M | |
| Selling And Marketing Expenses | 1.4M | 1.3M | 100K | 200K | 5.1K | 4.8K | |
| Tax Provision | (13.1M) | (7.8M) | (5.8M) | 301K | 183K | 192.2K | |
| Net Interest Income | (9.5M) | (15.3M) | (17.3M) | (18.1M) | (18.1M) | (19.0M) | |
| Interest Income | 103K | 48K | 81K | 68K | 61.2K | 71.2K | |
| Discontinued Operations | (16.3M) | (23.1M) | (51.2M) | (33.2M) | (29.9M) | (31.4M) | |
| Net Income From Continuing Ops | (38.2M) | (32.7M) | (46.3M) | (69.0M) | 9.3M | 9.8M | |
| Reconciled Depreciation | 18.8M | 19.9M | 17.9M | 13.5M | 8.9M | 12.6M | |
| Net Income Applicable To Common Shares | (38.2M) | (32.7M) | (97.4M) | (102.2M) | (92.0M) | (87.4M) |
Pair Trading with Lifecore Biomedical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lifecore Biomedical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lifecore Biomedical will appreciate offsetting losses from the drop in the long position's value.Moving against Lifecore Stock
| 0.8 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.79 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.79 | TCHH | Trustcash Holdings | PairCorr |
| 0.78 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.76 | AGL | agilon health Buyout Trend | PairCorr |
The ability to find closely correlated positions to Lifecore Biomedical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lifecore Biomedical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lifecore Biomedical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lifecore Biomedical to buy it.
The correlation of Lifecore Biomedical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lifecore Biomedical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lifecore Biomedical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lifecore Biomedical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Lifecore Stock Analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.